Pharmaceutical Executive July 22, 2024
The company received the money through a government project agreement.
Antheia announced that it has received $17 million in funding to be used for projects focused on building domestic pharmaceutical production sites.1 The pharmaceutical ingredient manufacturer obtained the funding through the Biopharmaceutical Manufacturing Preparedness Consortium, and it reports that it has received matching support from strategic investors.
The development of domestic ingredient manufacturing sites is considered by many in the the industry to be an important step in strengthening the national pipeline and preventing (or limiting) future drug shortages.
In a press release, Antheia CEO and co-founder Christina Smolke said, “Biotechnology has a critical role to play in U.S. national and economic security. With the support of both the public...
Today's Sponsors
Today's Sponsor